Scilex CEO issues letter to stockholders

Scilex Holding issued a letter from Jaisim Shah, its Chief Executive Officer and President, to its stockholders highlighting the Company’s accomplishments in 2023 and its forward outlook for 2024. “I would like to express my deepest gratitude for your unwavering support, patience, and invaluable feedback throughout the transformative year in 2023. It is our hope that this communication serves as both a reflection on Scilex’s significant strides in the past year and an insightful preview into the challenges and opportunities that lie ahead in 2024… As we continue to navigate the complexities of the pharmaceutical landscape, your role as stockholders in this journey is invaluable. Thank you for being an integral part of our mission and for your unwavering belief in our vision. Together, we are not just witnessing, but actively shaping, a pivotal chapter in healthcare history… We accomplished all of the goals that we set out at the beginning of 2023… Outlook for 2024… Despite the challenges that remain ahead, we are setting ambitious goals for the Company in 2024, including: Expected launch of Gloperba… Seek FDA approval for the modification of Gloperba… Continue to grow our gross sales with a goal of exceeding $200 million.Seek FDA approval of ELYXYB in acute pain in the U.S… Continue to develop our novel clinical pipeline… Initiation of ELYXYB pediatric study for migraine. Finalize plan with FDA for Phase 2/3 study for SP-103 in acute pain. Initiation of SP-102 chemistry, manufacturing and controls activities for commercial scale manufacturing for NDA filing in the U.S. File ZTlido applications in ex-US markets… Prepare for the next major international change affecting the demand for non-opioid therapeutics and be ready to capitalize on that change. Continue to enhance our product portfolio by in-licensing and out-licensing commercial products. Continue to enhance stockholder value and optimize our capitalization structure…. In closing, my heartfelt thanks go to the remarkable team at Scilex. Your unwavering dedication, creativity, and resilience are the driving forces behind our success. To our partners, our stockholders, and our dedicated board members: thank you for your confidence in us as we continue to forge ahead with our mission.”